Reparixin for myelofibrosis patients who can’t use JAK inhibitors
Part of Blood & lymphatic clinical trials.
This Phase 2 study tests reparixin, a drug aimed at reducing problems caused by myelofibrosis (bone marrow scarring). It focuses on people who have intermediate-2 or higher risk myelofibrosis and either didn’t respond to JAK inhibitor treatment or can’t tolerate it, to see if symptoms and disease markers improve.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and are able and willing to sign the consent form.
- You have confirmed primary myelofibrosis or certain post-treatment myelofibrosis (post-ET or post-PV), with intermediate-2 or higher risk disease.
- Your daily functioning is good enough for study care (ECOG score 0–2).
- You must be willing to do a bone marrow biopsy for screening (or provide one done within the last 90 days).
- You have tried JAK inhibitor treatment (or couldn’t use it) and it wasn’t working well enough or caused side effects that stopped you from continuing.
- Your organs and blood counts are sufficient (specific lab thresholds) and you have a life expectancy of at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called revumenib, either alone or combined with a JAK inhibitor, for people with myelofibrosis that is still active despite standard treatment. The goal is to see if revumenib can better control symptoms, reduce spleen size, or improve blood counts.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests an experimental drug called AJ1-11095 for people with myelofibrosis who no longer respond to a type of JAK2 inhibitor. It aims to see if the drug can shrink the spleen, improve symptoms, and be safe.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
This trial tests a new drug called RVU120 for people with myelofibrosis that has not responded well to standard JAK inhibitor treatment. It aims to shrink the spleen and improve symptoms.
This study tests a new combination of two drugs, tagraxofusp and pacritinib, for people with myelofibrosis who have already tried a JAK inhibitor without enough benefit or who couldn't take one. The goal is to see if the combination can shrink the spleen and improve symptoms.
Hear when a new Myelofibrosis (PMF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.